Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals has reported Total Non-Current Liabilities for 18 years, with the latest figure at $7.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 12.89% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $7.3 billion (up 12.89% YoY), and the FY2025 full-year result was $7.3 billion, up 6.56% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $7.3 billion, roughly flat from $7.3 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $7.3 billion in Q3 2025, with the low at $5.6 billion in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $6.5 billion, with a median of $6.5 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities increased 27.92% in 2023 and dropped 8.91% in 2024.
• Tracing REGN's Total Non-Current Liabilities over 5 years: stood at $5.9 billion in 2022, then rose by 5.76% to $6.3 billion in 2023, then rose by 9.3% to $6.8 billion in 2024, then rose by 6.56% to $7.3 billion in 2025, then increased by 0.49% to $7.3 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.

Peer Comparison